FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:730-731 February 12, 2009 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Hays, J. T. PubMed Citation

To the Editor: In the November 6 issue, Hays and Ebbert review the use of varenicline (Chantix) for tobacco dependence.¹ Although this review highlights the role of varenicline in achieving abstinence, we think that the presentation of neuropsychiatric side effects is understated. Neuropsychiatric side effects with varenicline were first publicly reported by the Food and Drug Administration (FDA) on November 20, 2007. In a public health advisory issued on February 1, 2008, the agency stated, "As FDA's review of the data has progressed it has become increasingly likely that the severe changes in mood and behavior may be related to . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.